Skip to main content
. 2015 Jun 18;10(6):e0128805. doi: 10.1371/journal.pone.0128805

Fig 8. Effect of BCAA on the dexamethasone-induced protein degradation pathway in the GH-treated SDRs.

Fig 8

A. In the GH-treated SDR, Dex increased Bnip3 mRNA in EDL muscles, and BCAA reversed this Dex-induced increase in Bnip3 mRNA. BCAA did not influence the Bnip3 mRNA level. B. Dex increased the atrogin-1 mRNA level, and BCAA decreased this Dex-induced increase in atrogin-1 mRNA in EDL muscles. C. Dex increased MuRF1 mRNA in EDL muscles. BCAA exhibited a trend toward decreasing this Dex-induced rise in MuRF1 mRNA, but it was not significant. BCAA increased MuRF1 mRNA in soleus muscles. D and E. Dex increased the REDD1 and REDD2 mRNA levels, and BCAA attenuated the Dex-induced increase in REDD2 mRNA. F, G and H. Dex elevated FoxO3 and FoxO4 mRNA levels and exhibited a tendency to increase the FoxO1 mRNA level. BCAA reversed the Dex-induced elevations of the FoxO3 and FoxO4 mRNA levels. I and J. Neither Dex nor BCAA exhibited a significant influence on myostatin or IGF-I mRNA levels. Black column: EDL muscles, gray column: soleus muscles. *, P < 0.05 vs. control group; ¶, P < 0.05 vs. Dex-treated group.